Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BeiGene, Ltd.
  6. News
  7. Analyst Reco.
    BGNE   US07725L1026

BEIGENE, LTD.

(BGNE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Analyst Recommendations on BEIGENE, LTD.
10/14BEIGENE : SVB Leerink Adjusts Price Target on BeiGene to $414 From $417, Maintains Outperf..
MT
10/12BEIGENE : Bernstein Starts BeiGene at Outperform With $431 Price Target
MT
08/16BEIGENE : Morgan Stanley Adjusts Price Target on BeiGene to $407 From $409, Maintains Over..
MT
06/14BEIGENE : SVB Leerink Adjusts BeiGene's Price Target to $417 from $388, Keeps Outperform R..
MT
06/03BEIGENE : Morgan Stanley Adjusts Price Target on BeiGene to $409 From $357, Maintains Over..
MT
05/10BEIGENE : Morgan Stanley Adjusts BeiGene's Price Target to $357 from $375, Keeps Overweigh..
MT
03/16BEIGENE : HSBC Adjusts BeiGene's Price Target to $385 from $296, Keeps Buy Rating
MT
03/08BEIGENE : China Renaissance Initiates Coverage on BeiGene With Buy Rating
MT
03/01BEIGENE : CLSA Downgrades BeiGene to Underperform From Outperform, Adjusts Price Target to..
MT
02/18BEIGENE : Cowen & Co. Adjusts Price Target on BeiGene to $429 From $348, Maintains Outperf..
MT
01/19BEIGENE : Morgan Stanley Adjusts BeiGene PT to $375 From $310, Maintains Overweight Rating
MT
2020BEIGENE : Ladenburg Thalmann Upgrades BeiGene to Buy From Neutral; Price Target is $278
MT
2020BEIGENE : SVB Leerink Adjusts BeiGene's Price Target to $327 From $240, Keeps at Outperfor..
MT
2020BEIGENE : Morgan Stanley Adjusts BeiGene PT to $310 From $270, Maintains Overweight Rating
MT
2020BEIGENE : Ladenburg Thalmann Downgrades BeiGene to Neutral from Buy
MT
2020BEIGENE : Piper Sandler Downgrades BeiGene to Underweight From Neutral; Price Target is $1..
MT
Analysis
China's biotech sector comes of age with big licensing deals, global ambitions
Upcoming event on BEIGENE, LTD.
11/11/21Q3 2021 Earnings Release (Projected)
Upcoming sector events
10/28/21GILEAD SCIENCES, INC. : Q3 2021 Earnings Release
10/29/21WUXI APPTEC CO., LTD. : Q3 2021 Earnings Release
11/02/21VERTEX PHARMACEUTICALS INCORPORATED : Q3 2021 Earnings Release
11/04/21REGENERON PHARMACEUTICALS, INC. : Q3 2021 Earnings Release
Sector
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Bio Therapeutic Drugs